Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Postherpetic neuralgia Stories

2013-07-26 20:21:40

NEWARK, Calif., July 26, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced it has filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Banner Pharmacaps Inc. and Watson Laboratories, Inc. Banner Pharmacaps has filed an Abbreviated New Drug Application (ANDA) with the FDA to market generic Zipsor(® )(diclofenac potassium) 25mg capsules and has granted to Watson Laboratories exclusive rights to the proposed...

2013-07-08 04:21:46

CAMBRIDGE, England, July 8, 2013 /PRNewswire/ -- Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia (PHN). Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd. The trial is a randomised...

2013-07-03 12:24:23

NEWARK, Calif., July 3, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the JMP Securities Healthcare Conference at the St. Regis Hotel in New York City. The presentation at the JMP conference is scheduled for 11:30 am EDT (8:30 am PDT) on Tuesday, July 9, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be...

2013-06-11 08:31:11

NEWARK, Calif., June 11, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Wells Fargo Securities 2013 Healthcare Conference at the Intercontinental Hotel in Boston, MA. The presentation at the Wells Fargo conference is scheduled for 11:15 am EDT (8:15 am PDT) on Wednesday, June 19, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of...

2013-05-28 16:26:28

NEWARK, Calif., May 28, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Jefferies 2013 Global Healthcare Conference at the Grand Hyatt in New York City. The presentation at the Jefferies conference is scheduled for 4:30 pm EDT (1:30 pm PDT) on Monday, June 3, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be...

2013-05-22 08:27:23

AACHEN, Germany, May 22, 2013 /PRNewswire/ -- Healthcare professionals who would like to know more about the topical treatment of postherpetic neuralgia (PHN) can now find useful information online. PHN is a chronic disabling pain condition with symptoms often described as burning, stabbing, or shooting pain, and caused by a previous herpes zoster infection (commonly known as shingles). The new website answers questions like "Why is PHN often misdiagnosed?" "Which questions...

2013-05-16 08:27:46

NEWARK, Calif., May 16, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the UBS Global Healthcare Conference at the Sheraton New York Hotel in New York City. The presentation at the UBS conference is scheduled for 10 am EDT (7 am PDT) on Tuesday, May 21, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived...

2013-05-01 08:31:15

NEWARK, Calif., May 1, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2013 financial results after the market closes on Wednesday, May 8, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live...

2013-04-23 08:33:29

CAMBRIDGE, England, April 23, 2013 /PRNewswire/ -- Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia (PHN). Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd. The trial is a randomised...

2013-04-10 13:55:36

Shingles vaccine is associated with reduction in both postherpetic neuralgia and herpes zoster, but uptake in the US is low A vaccine to prevent shingles may reduce by half the occurrence of this painful skin and nerve infection in older people (aged over 65 years) and may also reduce the rate of a painful complication of shingles, post-herpetic neuralgia, but has a very low uptake (only 4%) in older adults in the United States, according to a study by UK and US researchers published in...


Latest Postherpetic neuralgia Reference Libraries

69_7b87211f9314eacab994d465558a3a1b
2011-01-24 12:56:26

Herpes zoster (or zoster), is known as shingles or zona and is a viral disease characterized by painful skin rash with blisters in a limited area on one side of the body. Initial infection causes chickenpox. Once chickenpox is over the virus remains in the body and can cause shingles. It can become latent in the nerve cell bodies and sometimes in the dorsal root, cranial nerve, or autonomic ganglion. Years after initial infection, another breakout can cause a painful rash. The rash usually...

More Articles (1 articles) »